Conviction
$ Value
$33K
Shares
4,447
Price
$8
Filed
Nov 17
▶ Why this score? (10/10)
- ✓ Open market buy (+3)
- ✓ C-suite insider (+2)
- ✓ Director (+1)
- ✓ 10%+ owner (+1)
- ✓ Cluster: 3 insiders buying (+2)
- ✓ Not a 10b5-1 plan (+1)
Insider
Name
ALAM JOHN J
Title
CEO & President
CIK
0001197014
Roles
Transaction Details
Transaction Date
2025-11-13
Code
P
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
1,471,578
Footnotes
Shares purchased in open-market transactions. | Includes 1,471,578 shares held jointly by the Reporting Person and his spouse, Dr. Sylvie Gregoire, PharmD., a member of the Issuer's Board of Directors. | Includes 1,693 shares held by the John J. Alam Roth IRA. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.41 to $7.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range. | Includes 1,707 shares held by the Sylvie Gregoire Roth IRA. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.44 to $7.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range.
Filing Info
ALAM JOHN J's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-11 | CRVO | A | $0 |
| 2025-11-17 | CRVO | ▲ | $91K ★ |
| 2025-11-17 | CRVO | ▲ | $91K |
| 2025-11-14 | CRVO | ▲ | $13K |
| 2025-11-14 | CRVO | ▲ | $13K |
| 2025-11-13 | CRVO | ▲ | $33K |
| 2025-11-12 | CRVO | ▲ | $41K |
| 2025-06-23 | CRVO | A | $0 |
Other Insiders at CRVO (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
ALAM JOHN J
CEO & President
|
— | — | 2026-02-11 |
| Gregoire Sylvie | — | — | 2026-02-11 |
|
Blackburn Kelly
EVP, Clinical Development
|
— | — | 2026-02-11 |
|
ELDER WILLIAM ROBERT
CFO, GC & Secretary
|
— | — | 2026-02-11 |
|
De Rosch Mark
EVP, RA and GA and PgM
|
— | — | 2026-02-11 |
|
Winton Matthew
Chief Commercial and Business
|
— | — | 2026-02-11 |